Administration of riboflavin-producing lactic acid bacteria prevents tnbs-induced colitis in mice

R. LEVIT; G. SAVOY DE GIORI; A. DE MORENO DE LEBLANC; J.G. LEBLANC

Egmond aan Zee

Congreso; 12th International Symposium on Lactic Acid Bacteria; 2017

Royal Netherlands Society for Microbiology (KNVM) and the Federation of European Microbiological Societies(FEMS)

Inflammatory bowel diseases (IBD), which include Crohn?s disease (CD) and ulcerative colitis (UC), are a group of chronic disorders characterized by inflammation of the gastrointestinal tract. Pathogenesis of IBD is not yet fully understood but several studies have proposed the overproduction of reactive oxygen species (ROS) as a key factor in the development of IBD. It has been shown that certain strains of acid lactic bacteria (LAB) can produce beneficial compounds in foods or in the gastrointestinal tract such as riboflavin, a vitamin with reported antioxidant and antiinflammatory actions, and this could be a tool against IBD. The aim of this study was to evaluate the effect of administration of soymilk fermented by a riboflavin-producing strain, and individual probiotic suspensions of different riboflavin-producing strains (not in a food matrix)  in a colitis mouse model. Mice were intrarectally inoculated with TNBS to induce intestinal inflammation or ethanol for the control mice, and orally administered with soymilk fermented by Lactobacillus plantarum (Lp) CRL2130 or individual suspensions of Lp CRL2130, L. paracasei CRL76, L. bulgaricus CRL871, Streptococcus (St.) thermophilus CRL803. Weight loss, extent of intestinal damage and number of iNOs+ cells, microbial translocation to liver and cytokines levels in intestinal fluids were evaluated. Results showed that administration of both the soymilk fermented by Lp CRL2130 and either one of the four riboflavin-producing strains reduce de intestinal damage caused by TNBS compared to controls with unfermented soymilk, soymilk fermented by a non riboflavin-producing strain and non bacterial treatment. Administration of commercial riboflavin showed similar beneficial effects. In conclusion our results show that the administration of riboflavin-producing strains can prevent colitis in mice either when administered in a food matrix or as probiotic suspension suggesting its possible use in a pharmaceutical formulation